We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

317 hedge funds and large institutions have $2.45B invested in Takeda Pharmaceutical in 2019 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 101 increasing their positions, 98 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 98

0.14% less ownership

Funds ownership: 9.2% → 9.06% (-0.14%)

4% less call options, than puts

Call options by funds: $78.2M | Put options by funds: $81.2M

4% less capital invested

Capital invested by funds: $2.57B → $2.45B (-$114M)

9% less funds holding

Funds holding: 347 → 317 (-30)

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

46% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 61

Holders
317
Holders Change
-30
Holders Change %
-8.65%
% of All Funds
6.95%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.11%
New
33
Increased
101
Reduced
98
Closed
61
Calls
$78.2M
Puts
$81.2M
Net Calls
-$3.01M
Net Calls Change
-$19.4M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$26.6M
2
GC
GMT Capital
Georgia
+$20.4M
3
AC
Adelphi Capital
United Kingdom
+$18.3M
4
GCM
Glenview Capital Management
New York
+$17.5M
5
Renaissance Technologies
Renaissance Technologies
New York
+$16.1M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$36.4M
2
LP
LMR Partners
United Kingdom
-$35.1M
3
NMC
Nine Masts Capital
Hong Kong
-$26.1M
4
MC
Maverick Capital
Texas
-$15.9M
5
Morgan Stanley
Morgan Stanley
New York
-$15.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
VNA
301
Valley National Advisers
Pennsylvania
$1K – – –
LWM
302
Liberty Wealth Management
California
$1K +$259 +15 +41%
Bessemer Group
303
Bessemer Group
New Jersey
$1K +$536 +31 +69%
GAM
304
Gemmer Asset Management
California
$1K +$1.07K +62 New
LFG
305
Larson Financial Group
Missouri
$1K +$1.21K +70 New
CFGS
306
Concourse Financial Group Securities
Alabama
$1K +$1.5K +87 New
ED
307
Exane Derivatives
France
$516 – – –
GT
308
Glenmede Trust
Pennsylvania
$175 -$865 -50 -0.5%
NMC
309
Nine Masts Capital
Hong Kong
– -$26.1M -1,474,286 Closed
MP
310
MFN Partners
Massachusetts
– -$13.9M -785,000 Closed
AllianceBernstein
311
AllianceBernstein
Tennessee
– -$9.7M -548,154 Closed
PC
312
Polar Capital
United Kingdom
– -$7.48M -422,615 Closed
Millennium Management
313
Millennium Management
New York
– -$3.32M -187,487 Closed
HF
314
HRT Financial
New York
– -$1.11M -62,807 Closed
MME
315
Meag Munich Ergo
Germany
– -$993K -56,401 Closed
SSA
316
Schonfeld Strategic Advisors
New York
– -$971K -54,900 Closed
Brown Advisory
317
Brown Advisory
Maryland
– -$893K -50,445 Closed
LOAMU
318
Lombard Odier Asset Management (USA)
New York
– -$885K -50,000 Closed
GIA
319
Gateway Investment Advisers
Ohio
– -$669K -37,773 Closed
BAM
320
Blueshift Asset Management
New Jersey
– -$588K -33,232 Closed
JG
321
Jefferies Group
New York
– -$532K -30,053 Closed
CM
322
Caption Management
Oklahoma
– -$531K -30,000 Closed
KWA
323
KCS Wealth Advisory
California
– -$505K -28,531 Closed
SSG
324
Summit Securities Group
New York
– -$394K -22,802 Closed
AI
325
Atria Investments
North Carolina
– -$379K -22,369 Closed
11 12
13
14 15

TAK Hedge Fund Activity: Q3 2019 in Review

317 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q3 2019, worth a combined $2.45B — down 4.4% from $2.57B a quarter earlier.

Sellers outnumbered buyers: 61 funds closed out of TAK and 33 opened new positions — a net loss of 28 holders — while 98 trimmed existing stakes and 101 added.

The largest buyer was Goldman Sachs, adding an estimated $26.6M. The largest seller was Fidelity Investments, cutting an estimated $36.4M.

  • 317 institutional investors held Takeda Pharmaceutical (TAK) as of Q3 2019, down from 347 in Q2 2019.
  • Funds reported $2.45B of Takeda Pharmaceutical stock for Q3 2019, down 4.4% quarter-over-quarter.
  • 33 funds opened new Takeda Pharmaceutical positions in Q3 2019 and 61 closed out, a net change of -28 holders.
  • The largest Takeda Pharmaceutical buyer in Q3 2019 was Goldman Sachs, an estimated $26.6M added.
  • The largest Takeda Pharmaceutical seller in Q3 2019 was Fidelity Investments, an estimated $36.4M sold.

Based on aggregated 13F filings for Q3 2019.